Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions for plastics, chemicals and energy, today announced that I6001, a biobased polymeric modifier for PVC (polyvinyl chloride) formulations based on Metabolix PHA resin, is now available for shipment to customers. Metabolix designed I6001 as a performance additive to improve the mechanical and environmental performance characteristics of PVC. With a diverse use pattern ranging from construction materials to medical applications, PVC has an estimated market demand of approximately 35 million metric tons per year.
Metabolix researchers recently developed a series of PHA-based polymeric modifiers and presented data demonstrating very good miscibility with PVC and significant improvements in the modification and processing of PVC. Based on these findings, Metabolix developed I6001 polymeric modifier which significantly improves impact resistance and toughness in rigid and flexible PVC applications without compromising PVC transparency or UV stability. I6001 also may serve as a PVC processing aid due to its excellent miscibility and shear melting with PVC. Additional benefits of I6001 include plasticization, low modifier volatization and low extractables. I6001 is 85 percent biobased and is now available commercially.
Metabolix is developing a series of second generation products in the modifier space which the Company plans to launch in 2013 in conjunction with the planned start-up of PHA biopolymer manufacturing in Spain.
“As our new polymeric modifier for PVC, I6001 contributes renewable content while delivering an impressive set of processing advantages and performance characteristics,” said Bob Engle, vice president, commercial development of biopolymers at Metabolix. “We look forward to working with customers to identify suitable applications for PVC formulations using our polymeric modifiers. Next year, we are planning to introduce additional performance additives with very high biocontent for PVC and other commercially important resins to underscore our commitment to providing customers with sustainable, high-performance products that enable them to satisfy consumer demands, differentiate brands and meet evolving government regulations.”
Product information on I6001 including a data sheet and processing guide can be found on www.metabolix.com.
Metabolix, Inc. is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries. Metabolix is developing and commercializing a family of high-performance biopolymers targeted to the markets for film and bag applications, performance additives and functional biodegradation. Metabolix’s biobased chemicals platform utilizes its novel “FAST” recovery process to enable the production of cost-effective, “drop-in” replacements for petroleum-based industrial chemicals. The Company is also developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.
For more information, please visit www.metabolix.com. (MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the ability to develop, manufacture, and market PHA as polymeric PVC modifiers and performance additives,constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.Business Wire
Last updated on: 18/12/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.